Compare AbbVie Inc (ABBV) vs YieldMax AMZN Option Income Strategy ETF (AMZY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs YieldMax AMZN Option Income Strategy ETF — how do they compare? AbbVie Inc trades at $248.34 (market cap $441.94B), while YieldMax AMZN Option Income Strategy ETF trades at $11.29. The key difference: AbbVie Inc pays a 2.77% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and AbbVie Inc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | AMZY | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $263.58 | $15.75 |
52-Week Low | $197.38 | $9.98 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
AMZY trades at $11.29, down 2.84% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides weekly dividend distributions, with recent payouts ranging from $0.06 to $0.14, supporting high yield but raising sustainability concerns. Key support is at $11, with resistance at $12, as the RSI indicates potential overbought conditions near-term.
The outlook for AMZY hinges on its ability to maintain high dividend yields without eroding net asset value. Risks include NAV erosion from its synthetic option strategy and underperformance versus Amazon stock. Analyst sentiment is cautious due to structural drawbacks, making it suitable only for income-focused investors aware of the trade-offs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →
